The Register has covered Matrix and its commercial Element side quite a few times over the years, but we thought it might make things a little clearer to first explain the two sides of the Matrix ...

Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary Matrix-M adjuvant technology for use in up to two disease areas. The ...

JHipster 9.0.0-beta.2 deprecates the first beta to fix generator stability issues while advancing the platform to Spring Boot 4.0.2 and a new baseline of Java 21 (plus updated WebSocket security and ...

Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...

Security devs forced to hide Boolean logic from overeager optimizer FOSDEM 2026 The creators of security software have ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

Discusses Preliminary Financial Results, Churn Impact, and Strategic Progress in Key Verticals February 3, 2026 8:00 AM ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Having personally tested ...